AstraZeneca may resume U.S. COVID-19 vaccine trial this week

According to reports from four Reuters sources, AstraZeneca's vaccine trial in the U.S. could continue as early as this week. 

The drugmaker's large, late-stage trial has been on hold since September 6, after a participant in the company’s UK trial reportedly contracted transverse myelitis, a rare spinal inflammatory disorder.

Sources also say that the FDA is requiring trial researchers to add information about the incident to consent forms signed by participants.

Read the Reuters report